Background: Physicians have prescribed anticholinergic agents such as benztropine, procyclidine, biperiden and trihexyphenidyl for treatment and prophylaxis of antipsychotic-induced extrapyramidal symptoms (EPS) for decades. Anticholinergic agents can however worsen tardive dyskinesia and cause many adverse effects, including cognitive impairment. Previous studies of anticholinergic discontinuation in patients with schizophrenia receiving antipsychotics have yielded a wide range of EPS relapse rates. Improvement in cognition after anticholinergic withdrawal was observed in some studies.
Objective: This study evaluated the effect of anticholinergic discontinuation on movement disorders, cognition and general psychopathology after a 4-week taper in 20 outpatients with schizophrenia or schizoaffective disorder treated with antipsychotics.
Results: Eighteen of twenty patients successfully discontinued their anticholinergic medication; two did not because of akathisia. Repeated measures analysis of variance did not show a significant effect of anticholinergic discontinuation on total Extrapyramidal Symptoms Rating Scale score or on the Parkinsonism, Akathisia, Dystonia or Tardive Dyskinesia subscales. However, significant improvement was found on the Brief Assessment of Cognition in Schizophrenia composite z score at weeks 6, 8 and 12 compared with baseline. Significant improvements were seen on the motor and the symbol-coding tasks. No significant effects were observed on the Positive and Negative Syndrome Scale, Clinical Global Impression - Severity and Clinical Global Impression - Improvement scales.
Conclusion: In this 12-week study of anticholinergic discontinuation in 20 outpatients with schizophrenia or schizoaffective disorder, gradual decrease and discontinuation of anticholinergics led to a positive effect on cognition. There were no adverse consequences on general psychopathology and no significant differences for 18 of 20 subjects on movement disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257986 | PMC |
| http://dx.doi.org/10.1177/2045125314553611 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the 3-Year Continuation Rate and Discontinuation Factors Between Vibegron and Mirabegron in Patients With Overactive Bladder: A Retrospective Follow-Up Study in a Rehabilitation Hospital in Japan.
Low Urin Tract Symptoms
January 2025
Department of Urology, Hyogo Prefectural Central Rehabilitation Hospital, Kobe, Hyogo, Japan.
Objectives: The objective of this study is to compare the 3-year continuation rate and discontinuation factors between vibegron and mirabegron in patients with overactive bladder in a rehabilitation hospital in Japan.
Methods: The 3-year continuation rate of the target drugs and reasons for discontinuation as well as patients' backgrounds and adverse effects were evaluated retrospectively from the medical records between September 2018 and December 2020. After selecting patients according to our inclusion and exclusion criteria, 136 cases taking mirabegron and 82 taking vibegron were adjusted for intergroup variability by propensity score matching.
Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study.
BMJ Open
December 2024
Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, London, UK
Objectives: To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan.
Design: Retrospective, new-user, active comparator, observational cohort study using inverse probability of treatment weighting.
Setting: Health insurance claims data from the Medical Data Vision Co.
Brazilian best practice guidelines for amblyopia diagnosis and management.
Arq Bras Oftalmol
November 2024
Pediatric Ophthalmology Sector, Hospital de Olhos do Paraná, Curitiba, PR, Brazil.
This study aimed to propose a guideline for amblyopia treatment and follow-up. Studies show that amblyopia leads to a series of perceptual deficits, including loss of visual acuity, stereoacuity, and contrast sensitivity. Perceptual changes are also found in the sound eye, such as those involving the types of motion perception.
View Article and Find Full Text PDFScopolamine animal model of memory impairment.
Behav Brain Res
February 2025
Department of Neurobiology and Biophysics, Institute of Biosciences, Life Sciences Center, Vilnius University, Lithuania. Electronic address:
Article Synopsis
- This study evaluates the effectiveness of the scopolamine-induced memory impairment model for Alzheimer's disease by examining behavioral changes associated with the illness, particularly apathy-like behavior.
- The researchers conducted tests on young male Wistar rats and compared their results with older rats to assess age-related behavior changes.
- The results indicated that scopolamine treatment increased locomotor activity and impaired object recognition memory, but did not replicate the apathy-like symptoms typically seen in Alzheimer's, showing limitations of this animal model in fully representing the disease.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!